Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Virtual Conference 2021 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#1877 TSC22D1 Expression and Association with Clinic-Pathological Features in Bronchial Carcinoids

Introduction: Bronchial carcinoids (BC), typical (TC) or atypical (AC), are rare neoplasms arising from neuroendocrine cells spread in the respiratory epithelium Microarray data analysis obtained comparing a pool of TC with a pool of AC samples showed TSC22D1 down-regulation in AC samples. The role of TSC22D1 in neuroendocrine tumors is unknown.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Zatelli M

Authors: Falletta S, Gentilin E, Riva E, Bresciani G, Degli E,

Keywords: TSC22D1, bronchial carcinoids, aggressiviness,

#1494 CDK-Inhibitors as New Therapeutic Treatment for Human Bronchial Carcinoids

Introduction: Bronchial Carcinoids (BC) are still orphan of medical therapy. We previously demonstrated that 70% of primary BC cultures are sensitive to Everolimus (E), an mTOR inhibitor, while 30% are not. We also observed that in 2 human BC cell lines, the NCI-H720 (sensitive to E) and NCI-H727 (resistant to E), mTOR resistance may be linked to a differential cell cycle protein expression (CyclinD1/E, CDK2/4, p27kip1/p27kip1phospho-Ser10), which is higher in BC resistant to E as compared to sensitive ones, suggesting an impaired p27 function

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: BENFINI K

Authors: Benfini K, Gentilin E, Riva E, Di Pasquale C, Falletta S,

Keywords: Bronchial Carcinoid, Medical Therapy, mTOR Resistance, CDK inhibitors,

#1462 Cross-Talk Between EGFR and IGF1R Influences the Response to RTK Inhibitors in Bronchopulmonary (BP)-NET Cell Lines

Introduction: BP-NETs represent ~30% of all neuroendocrine tumors. BP-NET treatment is challenging due to onset of resistance to chemo and targeted therapies. EGFR and IGF1R had been associated with tumor onset and progression in several neoplasia.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Gagliano T

Authors: Gagliano T, Gentilin E, Benfini K, Falletta S, Di Pasquale C,

Keywords: BP-NET RTK,

#1173 Investigation of the Effects of Sunitinib on Pheochromocytoma and Paraganglioma Primary Cultures

Introduction: The main treatment for Pheochromocytoma and Paraganglioma is surgery. However these tumors are highly vascularized, suggesting the possible role for anti-angiogenic agents in the medical therapy. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor (TKI), mainly described to inhibit VEGFR

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Bellio M, Gagliano T, Feo C, Balboni F, Gentilin E,

Keywords: Sunitinib, Pheochromocytoma, Paraganglioma ,

#1163 Mitotane, Adrenolitic Drug, Inhibits Cell Survival and Function of Several Pituitary Cytotypes

Introduction: Mitotane (DDD) is an adrenolytic agent that is used for the treatment of adrenocortical carcinoma. We previously demonstrated that DDD affects thyrotrope cell viability and function. These data represent a possible explanation of the biochemical picture consistent with central hypothyroidism in patients undergoing DDD therapy. DDD also inhibits corticotrope cell viability by inducing caspase-mediated apoptosis and reduces POMC expression as well as basal and CRH-induced ACTH secretion. Cells originating from tissues different from pituitary are not sensitive to the inhibitory effects of DDD. Our data suggest that DDD inhibits cell survival and function of many pituitary cytotypes, acting with a generalized, but specific, toxic effect. The majority of male patients undergoing adjuvant DDD therapy show a clinical picture of hypogonadism, characterized by low free testosterone and unmodified LH concentration

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Gentilin E

Authors: Gentilin E, Gagliano T, Benfini K, Di Pasquale C, Falletta S,

Keywords: mitotane, adrenocortical cancer, pituitary,

Abstract Submissions in 2022

Abstract submissions for 2022 will open in September 2021!


The 19th Annual ENETS Conference in 2022 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.


Participants of the ENETS Virtual Conference 2021 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.